Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Tesofensine is a potent triple monoamine (noradrenaline/dopamine/serotonin) reuptake inhibitor that drives strong appetite suppression and fat loss, roughly twice the placebo-subtracted weight loss of older anti-obesity drugs in its phase 2 TIPO-1 trial (~10% at 0.5-1.0 mg over 24 weeks), a result its completed Phase 3 program has since corroborated. It is a powerful pharmacological metabolic/appetite tool rather than an anabolic. It has zero muscle-building or androgenic activity and works entirely through central stimulant pathways, and is WADA-prohibited as a stimulant (S6, added 2025). Rated 5, in line with other potent non-hormonal stimulant fat-burners (comparable to ephedrine), for meaningful fat-loss enhancement beyond natural capacity without any anabolic component.
Overview
A centrally acting triple monoamine reuptake inhibitor originally developed for Parkinson's and Alzheimer's disease, where patients unexpectedly lost weight. It was repurposed as an anti-obesity agent and produced some of the strongest weight-loss numbers seen for a single small-molecule drug in phase 2 trials. It works mainly by suppressing appetite, with a smaller effect on energy expenditure, and carries a stimulant-type side-effect profile (raised heart rate and blood pressure).
Important Warnings
- •Raises heart rate and blood pressure - monitoring is mandatory; avoid if hypertensive or cardiovascular disease
- •Do NOT stack with other stimulants (clenbuterol, ephedrine, yohimbine) - dangerous additive cardiovascular load
- •Do NOT combine with MAOIs, SSRIs or SNRIs - serotonergic/monoaminergic interaction risk
- •Very long half-life (~9 days) - drug and side effects accumulate and persist for weeks after stopping
- •Not FDA/EMA approved; grey-market product quality and dosing accuracy are unverified
- •Psychiatric effects (depressed mood in ~6% of trial participants at 0.5-1.0 mg, anxiety, insomnia) - avoid with a psychiatric history
Purpose & Use Cases
Appetite Suppression
Its primary and strongest effect: potent central appetite suppression that makes a caloric deficit easier to sustain.
Fat Loss
In the phase 2 TIPO-1 trial, 24 weeks produced placebo-subtracted weight loss of roughly 4.5% (0.25 mg), 9.2% (0.5 mg) and 10.6% (1.0 mg), about double what older obesity drugs achieved.
Metabolic Rate (secondary)
A smaller contribution from increased energy expenditure and fat oxidation on top of the appetite effect.
Benefits
- Very strong appetite suppression
- Among the largest phase-2 weight-loss results for a single agent (~10%)
- Once-daily dosing (very long half-life)
- Also improves glycemic markers in trials
- Effect builds and is sustained over weeks
Good to Know
It is NOT a peptide
Grey-market sellers often list tesofensine as a "weight-loss peptide." It is a small-molecule triple monoamine reuptake inhibitor - closer to a stimulant/antidepressant than to a peptide - and should be respected as a centrally acting drug.
Very long half-life means it accumulates
At ~9 days (active metabolite ~16 days), levels build for weeks before steady-state, so effects and side effects both intensify over time and linger for weeks after the last dose. Start low and be patient rather than chasing quick results.
Cardiovascular effects are the limiting factor
It reliably raises heart rate and blood pressure. Clinical trials specifically paired it with a beta-blocker (metoprolol, the "Tesomet" combination) to control this. It is unsuitable for anyone hypertensive or with cardiac disease.
Discovered by accident
It was originally developed for Parkinson's and Alzheimer's disease; the weight loss was a side effect noticed in those trials, which redirected it toward obesity.
Still investigational
Despite strong phase-2 results (~10% weight loss, roughly double older drugs) and a completed Phase 3 obesity program, tesofensine remains unapproved by the FDA and EMA; a Mexican (COFEPRIS) filing has been pending since 2023 with no approval yet granted. Anything sold to consumers today is unapproved research-grade material of uncertain purity.
The original 2008 trial carries a published "Expression of Concern"
The Lancet issued a formal Expression of Concern (2013) about the original TIPO-1 publication after a Danish Health and Medicines Authority inspection raised questions, including under-reporting of adverse effects. It has not been retracted, but it is a reason to treat the original efficacy/safety numbers with some caution alongside the later Phase 3 confirmation.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.25 – 0.25 mg/day |
| Intermediate | 0.25 – 0.5 mg/day |
| Advanced | 0.5 – 1 mg/day |
Phase 2 (TIPO-1) tested 0.25, 0.5 and 1.0 mg once daily; the later Phase 3 obesity program narrowed to just 0.25 and 0.5 mg, reflecting that 1.0 mg's extra weight loss comes with a disproportionate rise in cardiovascular and psychiatric side effects (insomnia, mood). 0.5 mg is the usual efficacy/tolerability sweet spot. The ~9-day half-life means the drug accumulates for weeks before steady-state, so start at 0.25 mg, escalate slowly, and remember that side effects (and blood-pressure changes) also persist for weeks after stopping. Blood-pressure and heart-rate monitoring is essential.
Side Effects
Increased Blood Pressure / Heart Rate
very commonThe dose-limiting effect. Therapeutic doses raised blood pressure ~1-3 mmHg and heart rate up to ~8 bpm on average, with larger increases at 1.0 mg. This is the reason trials paired it with a beta-blocker (metoprolol) and why it is unsuitable for people with hypertension or cardiac disease.
Monitor blood pressure and heart rate. Keep to lower doses. Trials mitigated this by co-administering metoprolol. Avoid if hypertensive or cardiovascular disease is present.
Insomnia
commonDose-dependent; most pronounced at 1.0 mg due to the stimulant, monoamine-elevating mechanism and long half-life.
Dose in the morning. Lower the dose. Avoid other stimulants.
Dry Mouth
very commonOne of the most frequently reported effects, dose-dependent, from noradrenergic activity.
Hydrate. Usually tolerable.
Mood Changes / Anxiety
commonDepressed mood, anxiety, agitation and irritability reported in the TIPO-1 trial, with roughly 6% of participants on the 0.5-1.0 mg doses developing depressed mood (including one case of major depression at the highest dose) - consistent with strong central monoamine and dopamine reuptake inhibition. Despite meaningful dopamine transporter occupancy (PET imaging shows ~60-80%+ striatal DAT occupancy at 0.5-1.0 mg), a human abuse-liability trial in recreational stimulant users found tesofensine's abuse potential was similar to placebo, suggesting lower classic-stimulant abuse liability than the mechanism alone would predict - though the mood/psychiatric effects still warrant caution.
Discontinue if mood deteriorates. Avoid in those with psychiatric history or on interacting antidepressants (MAOIs, SSRIs, SNRIs).
Nausea / GI Upset
commonNausea, diarrhea or constipation reported in the obese trial population.
Usually mild and transient; take with food.
Headache
commonCommonly reported during treatment.
Usually manageable; hydrate.
General Mitigation Strategies
The limiting issue is cardiovascular: tesofensine raises heart rate and blood pressure, so monitoring is mandatory and it should be avoided by anyone hypertensive or with cardiac disease (trials co-dosed a beta-blocker such as metoprolol specifically to blunt this). Start low (0.25 mg), escalate slowly, and respect the ~9-day half-life, effects and side effects build and linger for weeks. Do NOT combine with other stimulants (clen, ephedrine, yohimbine) or with serotonergic drugs (SSRIs/SNRIs/MAOIs) due to additive cardiovascular and serotonergic risk.
Support Supplements
Ancillary supplements commonly run alongside Tesofensine to manage side effects, support the target tissue, or fill nutrient demands it creates.
Beta-blocker (e.g. Metoprolol) / BP management
KeyDirectly counters the drug's rise in heart rate and blood pressure, the exact strategy used in tesofensine clinical trials (the Tesomet combination pairs it with metoprolol).
- Dose
- As prescribed
- Timing
- Daily alongside tesofensine
- When
- For managing cardiovascular effects; a prescription decision. Anyone using tesofensine should at minimum monitor BP/HR at home.
Magnesium & Hydration/Electrolytes
Supports cardiovascular tone and sleep, and offsets dry mouth/GI effects during an elevated adrenergic state.
- Dose
- Magnesium 200-400 mg/day; adequate fluids/electrolytes
- Timing
- Magnesium in the evening can help sleep
- When
- Supportive only; does not replace blood-pressure monitoring.
Post Cycle Therapy (PCT)
Not hormonal. Does not affect the HPTA. No PCT required.
How It Works
Tesofensine inhibits the presynaptic reuptake of noradrenaline, dopamine and serotonin (a triple/monoamine reuptake inhibitor of the phenyltropane class), with strongest activity at the noradrenaline transporter, then serotonin, then dopamine. By raising synaptic monoamines it indirectly stimulates alpha-1 adrenoceptor and dopamine D1 receptor pathways, which drives robust appetite suppression; a modest increase in resting energy expenditure and fat oxidation adds to the effect. The result is reduced food intake as the dominant mechanism of weight loss.
Fundamentals
Reference on the practices relevant to Tesofensine: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Not approved by the FDA, EMA, or any regulator worldwide. Its Phase 3 obesity program (via Saniona's partner Medix, doses 0.25/0.5 mg) reported positive topline results, and a new drug application has been under review by Mexico's COFEPRIS since 2023 (dossier resubmitted in 2025) with no approval granted as of mid-2026. Sold globally as an unregulated grey-market "research chemical."
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Tesofensine is listed as an example of a prohibited stimulant under S6 (added on the 2025 WADA Prohibited List) and appears increasingly in dietary supplements. Stimulants are prohibited in-competition only.
References
- Wikipedia - Tesofensine (pharmacology, half-life, TIPO-1 trial)
- PubMed - Tesofensine effect on energy metabolism and appetite (Sjodin et al.)
- PMC - Tesofensine appetite suppression via alpha-1 / D1 pathways (DIO rat)
- Obesity (Wiley) - Anti-hypertensive treatment preserves appetite suppression while preventing CV effects
- The Lancet - Expression of Concern: Effect of tesofensine on bodyweight loss (TIPO-1)
- Saniona - Tesofensine pipeline (Phase 3 obesity program, Medix/COFEPRIS status)